Xeris Biopharma (XERS) Competitors

Zealand Pharma A/S (NASDAQ:ZEAL) and Xeris Biopharma (NASDAQ:XERS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, community ranking, earnings, dividends, media sentiment, risk, valuation, institutional ownership and analyst recommendations.

Does the media prefer ZEAL or XERS?

In the previous week, Xeris Biopharma had 4 more articles in the media than Zealand Pharma A/S. MarketBeat recorded 4 mentions for Xeris Biopharma and 0 mentions for Zealand Pharma A/S. Zealand Pharma A/S's average media sentiment score of 1.08 beat Xeris Biopharma's score of 0.12 indicating that Zealand Pharma A/S is being referred to more favorably in the media.

Company	Overall Sentiment
Zealand Pharma A/S	Positive
Xeris Biopharma	Neutral

Do analysts prefer ZEAL or XERS?

Xeris Biopharma has a consensus target price of $4.87, indicating a potential upside of 59.04%. Given Xeris Biopharma's higher probable upside, analysts plainly believe Xeris Biopharma is more favorable than Zealand Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Xeris Biopharma	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has higher earnings and valuation, ZEAL or XERS?

Xeris Biopharma has higher revenue and earnings than Zealand Pharma A/S. Xeris Biopharma is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zealand Pharma A/S	$46.54M	17.59	-$161.99M	-$4.09	-4.30
Xeris Biopharma	$163.91M	2.78	-$62.26M	-$0.45	-6.80

Does the MarketBeat Community favor ZEAL or XERS?

Zealand Pharma A/S received 148 more outperform votes than Xeris Biopharma when rated by MarketBeat users. However, 69.76% of users gave Xeris Biopharma an outperform vote while only 65.69% of users gave Zealand Pharma A/S an outperform vote.

Company	Underperform	Outperform
Zealand Pharma A/S	Outperform Votes 291 65.69%	Underperform Votes 152 34.31%
Xeris Biopharma	Outperform Votes 143 69.76%	Underperform Votes 62 30.24%

Which has more volatility and risk, ZEAL or XERS?

Zealand Pharma A/S has a beta of 1.45, meaning that its stock price is 45% more volatile than the S&P 500. Comparatively, Xeris Biopharma has a beta of 2.7, meaning that its stock price is 170% more volatile than the S&P 500.

Do insiders and institutionals hold more shares of ZEAL or XERS?

1.7% of Zealand Pharma A/S shares are held by institutional investors. Comparatively, 42.8% of Xeris Biopharma shares are held by institutional investors. 2.2% of Zealand Pharma A/S shares are held by insiders. Comparatively, 4.6% of Xeris Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Is ZEAL or XERS more profitable?

Xeris Biopharma has a net margin of -33.69% compared to Zealand Pharma A/S's net margin of -565.44%. Zealand Pharma A/S's return on equity of -111.04% beat Xeris Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	-565.44%	-111.04%	-56.54%
Xeris Biopharma	-33.69%	-16,662.63%	-17.38%

Summary

Xeris Biopharma beats Zealand Pharma A/S on 12 of the 18 factors compared between the two stocks.